

# Jeffrey S Heier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9395664/publications.pdf>

Version: 2024-02-01

37  
papers

18,980  
citations

172457

29  
h-index

330143

37  
g-index

37  
all docs

37  
docs citations

37  
times ranked

7026  
citing authors

#	ARTICLE	IF	CITATIONS
1	MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. <i>Ophthalmology</i> , 2022, 129, 974-985.	5.2	28
2	Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab. <i>Ophthalmology</i> , 2021, 128, 1050-1059.	5.2	196
3	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2021, 10, 1355.	2.4	17
4	Altered Blood Flow in the Ophthalmic and Internal Carotid Arteries in Patients with Age-Related Macular Degeneration Measured Using Noncontrast MR Angiography at 7T. <i>American Journal of Neuroradiology</i> , 2021, 42, 1653-1660.	2.4	13
5	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 186-195.	5.2	306
6	Intravitreal Combined Aflibercept+ Anti-Platelet-Derived Growth Factor Receptor $\beta^2$ for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 211-220.	5.2	12
7	Visual Function Decline Resulting from Geographic Atrophy. <i>Ophthalmology Retina</i> , 2020, 4, 673-688.	2.4	44
8	Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies. <i>Ophthalmology Retina</i> , 2019, 3, 553-560.	2.4	4
9	Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection. <i>Journal of Vitreoretinal Diseases</i> , 2019, 3, 411-419.	0.7	3
10	Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study. <i>Ophthalmology Retina</i> , 2019, 3, 32-41.	2.4	19
11	Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018, 125, 1556-1567.	5.2	100
12	The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. <i>JAMA Ophthalmology</i> , 2017, 135, 268.	2.5	39
13	Vascular endothelial growth factor and diabetic macular edema. <i>Survey of Ophthalmology</i> , 2016, 61, 759-768.	4.0	54
14	Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. <i>Ophthalmology</i> , 2016, 123, 1856-1864.	5.2	65
15	EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 1542-1547.	1.7	23
16	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion. <i>Ophthalmology</i> , 2016, 123, 330-336.	5.2	204
17	Randomized Trial to Evaluate Tandoespiron in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study. <i>American Journal of Ophthalmology</i> , 2015, 160, 1226-1234.	3.3	53
18	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2015, 122, 2044-2052.	5.2	451

#	ARTICLE	IF	CITATIONS
19	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion. <i>Ophthalmology</i> , 2015, 122, 538-544.	5.2	281
20	Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design â€” HOME Study report number 1. <i>Contemporary Clinical Trials</i> , 2014, 37, 294-300.	1.8	56
21	Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion. <i>Ophthalmology</i> , 2014, 121, 1414-1420.e1.	5.2	237
22	Noninfectious Inflammation After Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual Outcomes. <i>American Journal of Ophthalmology</i> , 2014, 158, 733-737.e1.	3.3	69
23	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2014, 121, 2247-2254.	5.2	668
24	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	5.2	693
25	Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. <i>American Journal of Ophthalmology</i> , 2013, 155, 429-437.e7.	3.3	313
26	Ranibizumab for Macular Edema Due to Retinal Vein Occlusions. <i>Ophthalmology</i> , 2012, 119, 802-809.	5.2	417
27	Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>Ophthalmology</i> , 2012, 119, 1024-1032.	5.2	225
28	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 2537-2548.	5.2	1,947
29	Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 1089-1097.	5.2	94
30	The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. <i>Ophthalmology</i> , 2011, 118, 1098-1106.	5.2	143
31	Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. <i>Ophthalmology</i> , 2011, 118, 2453-2460.	5.2	623
32	Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. <i>Ophthalmology</i> , 2010, 117, 1102-1112.e1.	5.2	772
33	Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. <i>Ophthalmology</i> , 2010, 117, 1134-1146.e3.	5.2	938
34	Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. <i>Ophthalmology</i> , 2009, 116, 57-65.e5.	5.2	1,179
35	Ranibizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2006, 355, 1419-1431.	27.0	5,190
36	Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2006, 355, 1432-1444.	27.0	3,221

#	ARTICLE	IF	CITATIONS
37	A Pilot Study of Multiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema. <i>Ophthalmology</i> , 2006, 113, 1706-1712.	5.2	283